Structure-Activity Relationship Studies of CNS Agents, Part 23^[1]:

N-(3-Phenylpropyl)- and *N*-[(*E*)-Cinnamyl]-1,2,3,4-tetrahydroisoquinoline Mimic 1-Phenylpiperazine at 5-HT_{1A} Receptors

Jerzy L. Mokrosz*, Andrzej J. Bojarski, Sijka Charakchieva-Minol, Beata Duszynska, Maria J. Mokrosz, and Maria H. Paluchowska

Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna St., 31-343 Kraków, Poland

Key Words: 5-HT_{1A} receptor ligands, 1-arylpiperazines, N-substituted 1,2,3,4-tetrahydroisoquinolines, molecular modelling

Summary

The 5-HT_{1A} receptor affinities and ionization constants of a set of 1-arylpiperazine (4) 1,2,3,4-tetrahydroisoquinoline (6), and -quinoline (7) containing *N*-(ω -arylalkyl) or *N*-(*E*)-cinnamyl substituents as well as two morpholine derivatives (8a, 8b) were determined. It was shown that some tetrahydroisoquinoline (6c, 6d) and morpholine (8a) derivatives were 5-HT_{1A} ligands equipotentto 1-phenylpiperazine (4a) and 1,2,3,4,4a,5-hexahydropyrazino[1,2-*a*]indole (5). On the basis of molecular modelling studies it was also demonstrated that 6c, 6d and 8a mimicked very well the reference structures of 4a and its rigid analog 5. Another, more complex 1,2,3,4-tetrahydroisoquinoline derivative 3, which served as a model compound to confirm the previously reported 5-HT_{1A} binding mode of derivatives 1a-d and 2, had the highest 5-HT_{1A} affinity ($K_i = 6.7 \pm 0.5$ nM) of all the investigated compounds.

Introduction

The N-4 piperazine atom and an aromatic ring of simple 1-arylpiperazines are known to form a pharmacophore which is recognized by the 5-HT_{1A} receptor^[2]. However, our previous paper showed that a bioactive complex of some 4-substituted 1-arylpiperazines of type 1 with 5-HT_{1A} receptors may be formed by the piperazine nitrogen atom and the aryl substituent at position 1 of the 3(2H)-isoquinolinone moiety, instead of an aromatic substituent of the piperazine ring^[3]. In order to verify the proposed interaction mode of derivatives of type 1 with 5-HT_{1A} receptors, we also developed compound $2^{[3]}$. However, its 5-HT_{1A} affinity was fairly low (K_i = 911 nM)^[3], probably due to a very high basicity of the piperidine nitrogen atom. In fact, the determined basicity of *N*-propylpiperidine (at 37 °C) was $pK_a = 10.24 \pm 0.03^{[4]}$, whereas typical pK_a values of simple 1-arylpiperazines were within the range of $7.94 - 9.14^{[5]}$.

In search of new model compounds which mimic both the structure and 5-HT_{1A} affinity of 1-phenylpiperazine (4a) and its rigid analog (5), in the present paper we discuss some structure-activity relationships of compounds 4–8. In order to explain a fairly low 5-HT_{1A} affinity of 2 and previously proposed binding mode of derivatives 1a-d and 2 at the 5-HT_{1A} sites^[3] we also examined compound 3 which is the tetrahydroisoquinoline analog of 1c and 1d (Scheme 1).



Results and Discussion

Compounds 4e, 6d, 8a, and 8b were prepared by a novel synthetic method developed by Katritzky and coworkers^[6] and already adapted in our laboratory to preparation of derivative 4c^[1]. Reaction of 4d with cinnamaldehyde and benzotriazole gave both 4e and 4f. However, when 6a was used, only the cinnamyl derivative 6d was isolated with a low yield of 15%. By contrast, in the reaction between morpholine, crotonaldehyde and benzotriazole only the benzotriazole derivatives 8a,b were obtained (Scheme 2). N-Alkylation of 1-(m-chlorophenyl)-1,4-dihydro-3(2H)-isoquinolinone with N-(3-chloropropyl)-1,2,3,4-tetrahydroisoguinoline was carried out in the presence of KF supported on neutral Al₂O₃ as a catalyst in acetonitrile solution and gave 3 with a yield of 24% (Scheme 3). A simple condensation of the appropriate ω -phenylalkylbromide with **6a** or **7a** under reflux in *n*-butanol, in the presence of K₂CO₃, afforded **6b**,c and **7b**,c in a yield of 38-55% (Scheme 4).



Scheme 4

Our previous paper showed that 1-phenylpiperazine (4a) had the same, moderate 5-HT_{1A} affinity as its rigid analog 5 (Table 1)^[7]. 1-Arylpiperazines 4b and 4d were more active than 4a, and substitution with the N-(E)-cinnamyl group resulted in further enhancement of the observed 5-HT_{1A} affinity. On the other hand, compounds 6a and 7a were completely inactive. Replacement of the hydrogen atom in 6a with the 2-phenylethyl fragment markedly increased the 5-HT_{1A} affinity of **6b** up to a micromolar level. 3-Phenylpropyl and (E)-cinnamyl substituents were even more effective, as derivatives 6c and 6d reached almost the same affinity levels which were only 1.5-2 times lower than those of 4a or 5. A similar trend was observed in the case of 7a-c; however, the observed K_i values for 7b and 7c were very low. Of the two morpholine derivatives, only 8a showed a significant yet low micromolar 5-HT_{1A} affinity, whereas **8b** was completely inactive.

Some of the observed substituent effects may be explained by different ionization states of the investigated compounds under experimental conditions (pH = 7.4, temp. 37 °C). It was shown earlier that the apparent binding constants K_i depended on the concentration of the protonated species of a ligand molecule under experimental conditions, and the specific binding constants of the protonated form was defined by eq. (1)^[7,9].

$$K_i^{\rm AH+} = K_i / [1 + 10^{(7.4 - pKa)}]$$
(1)

Reference compounds 4a and 5 are almost fully ionized at pH = 7.4 and temp. 37 °C (>92%). By contrast, the inactive 1,2,3,4-tetrahydroquinoline (7a) is poorly ionized (0.27%)

Table 1. The 5-HT_{1A} binding data (K_i) and ionization constants (pK_a) for 8-OH-DPAT and **3-8**.

No.	$K_i [nM] \pm SEM^{[a]}$	$K_i^{AH+} [nM]^{[b]}$	pKa ^[c]
8-OH-D	PAT 1.4±0.2		
3	6.7 ± 0.5		[d]
4a ^[e]	378 ± 54	348	8.46
4b ^[f]	143 ± 6	131	8.42
4 c	76 ± 3		[d]
4d	$168 \pm 14^{[g]}$		8.86 ^[h]
4 e	78 ± 5		[d]
5 ^[e]	345 ± 13	329	8.73
6a	> 50 000		9.30 ^[h] ; 8.82 ^[i]
6b	2160 ± 35	≈ 860-1300 ^[j]	6.86 ^[i]
6c	582 ± 35	≈ 230–460 ^[j]	7.15 ^[i]
6d	768 ± 40	≈ 230–460 ^[j]	6.74 ^[i]
7a	> 50 000		4.84 ^[h]
7b	26 200 ± 5900		[d]
7c	11 400 ± 350		[d]
6c 582 ± 35 6d 768 ± 40 7a > 50 000 7b $26 200 \pm 5900$ 7c 11 400 \pm 350 morpholine -			8.17
8a	5700 ± 280	331	6.19
8b	> 50 000		6.31

^[a] Hill slopes: for 8-OH-DPAT and 3-6 0.89 $\le n_H \le 1.05$, for 7b, 7c, and 8a $n_H = 0.75$ and 0.81, respectively.

^[b] Calcd. from eq. (1).

^[c] Determined by a potentiometric titration^[8] in water at 37 °C; standard error $\leq \pm 0.03$.

^[d] Solubility of the base in both water and in 50% ethanol was too low to determine the pK_a value.

^[e] Data taken from ref.^[7].

^[f] Data taken from ref.^[9].

^[g] Ref.^[10].

- ^[h] Ref.^[5].
- ^[i] Determined in 50% ethanol at 37 °C.

^[j] The estimated values for 40-60% ionization in water (cf. discussion).

under the same conditions. Hence a very low concentration of the ionized species of 7b and 7c may account for their almost negligible 5-HT1A affinity. The 5-HT1A affinity of 8a is also low. However, the concentration of the ionized form of the latter compound (ionization percentage = 5.81%) cannot be neglected, and the calculated value $K_i^{AH+} = 331 \text{ nM}$ is the same as those calculated for 4a and 5: $K_i^{AH+} = 348$ and 329 nM, respectively^[7]. The concentration of the ionized form of 8b is similar (7.52%), hence the lack of activity in this particular case should be of a different nature. Although 1,2,3,4-tetrahydroisoquinoline (6a) is fully protonated at pH = 7.4 and temp. 37 °C (98.8%), it does not form a bioactive complex with 5-HT_{1A} receptors, as the crucial distance between the aromatic ring center and the nitrogen atom (d_{Ar-N}) = 3.8 Å) is below the critical value of 4.5 Å^[11]. The pK_a values for 6b-6d, determined in 50% ethanol, are lower by 1.67-2.08 units than that determined for 6a (Table 1). Hence it may be assumed that 6b-6d are ionized in water (under the experimental conditions) in about 40-60%. If this is the case, the $K_i^{AH+} \approx 230-460$ nM values for 6c and 6d are within the same range as those calculated for 4a and 5. However, the $K_i^{AH+} \approx 860-1300 \text{ nM}$ value for **6b** remains at least twice as low as those for **6c** and **6d**; again, this phenomenon appears to be of a different nature. In fact, molecular modelling studies have shed some light on the phenomenon in question.

Compounds 6b-6d, 8a, and 8b have a flexible structure, as shown by molecular mechanics calculations. In other words, a random search procedure generated a number of low-energy conformations, which passed the following criterion: $\Delta(\Delta H)$ \leq 5 kcal/mol (Table 2). Although the ranges of the two pivotal parameters, *i.e.* the distance between the aromatic system center and the nitrogen atom (d_{Ar-N}) and the deviation of the nitrogen atom from a plane of the aromatic ring system (h), formally match both the d_{Ar-N} and H values for 4a and 5, as well as the values reported by *Hibert et al.*^[12,13], the deviation h is usually very strong and indicates some folded conformations (except for 6d) which do not overlap the reference structure of 5 (Fig. 1a). Therefore only those conformations that met the additional criterion $h \leq 1$ Å were selected from all the generated ones. The data shown in Table 2 indicate that all the selected conformations of 6c, 6d and 8a mimic very well the rigid structure of 5 (Figs. 1b, c).

Table 2. Results of the molecular modelling of compounds 6b-6d, 8a and 8b.

No.	Number of conformations	d _{Ar-N} [Å] ^[a]	h [Å] ^[a]
4a ^[b]		5.68	0.81
5 ^[b]		5.50	0.06
6b	46 ^[c] 8 ^[d]	3.62–5.30 3.66–5.30	0.22-4.67 0.22-0.94
6c	35 ^[c]	3.10-6.29	0.65-3.88
	5 ^[d]	5.71-5.79	0.66-0.70
6d	43 ^[c] 27 ^[d]	5.736.13 5.736.13	0.09–2.06 0.09–0.83
8a	25 ^[c] 4 ^[d]	3.24-6.79 5.68-5.92	0.30–3.97 0.30–0.96
8b	20 ^[c] 2 ^[d]	3.61–6.97 6.54–6.68	0.66–3.88 0.66

^[a] Typical ranges reported for different classes of 5-HT_{1A} ligands: $d_{\text{Ar-N}} = 5.2-5.6 \text{ Å}, h = 0.2-1.6 \text{ Å}^{[12,13]}.$

^[b] Measured for the lowest energy conformer.

^[c] All the generated low-energy conformations [$\Delta(\Delta H) \leq 5$ kcal/mol].

^[d] The conformations that met the criterion: $h \leq 1$ Å.

Hence it may be concluded that molecular modelling results support the earlier findings that compounds **6c**, **6d** and **8a** are 5-HT_{1A} ligands equipotent to the reference compounds **4a** and **5**, as indicated by their K_i^{AH+} values. Furthermore, the d_{Ar-N} parameter of the inactive compound **8b** (*i.e.*, 6.54–6.68 Å) exceeds the typical range (*i.e.*, 5.68 Å for **4a** and 5.50 Å for **5**).



Figure 1. Superimposition of **6b** (a), **6c** (b), and **6d** (c) and the rigid reference structure of **5**. Cross marks indicate the position of the nitrogen atom of **6b-6d** in relation to the fixed position of the phenyl substituent. (a) All the generated conformations $[\Delta(\Delta H) \le 5 \text{ kcal/mol}]$; (b) and (c) – the conformations that met the criterion $h \le 1 \text{ Å}$.

The presented results clearly indicated that the tetrahydroisoquinoline N-atom may mimic the basic nitrogen atom of 1-arylpiperazine at the 5-HT_{1A} receptors. Therefore we have assumed that the tetrahydroisoquinoline moiety of derivative 3 could be better model than the piperidine fragment of compound 2 to confirm the previously proposed mode of interaction of derivatives 1a-d with 5-HT_{1A} receptors. Indeed, the 5-HT_{1A} affinity of 3 ($K_i = 6.7 \pm 0.5$ nM) is of the same order as those reported for 1c and 1d ($K_i = 1.7 \pm 0.1$ and 9.5 ± 0.6 nM, respectively)^[3], whereas the piperidine derivative 2 ($K_i = 911 \approx 34$ nM) was substantially less active at 5-HT_{1A} receptors than 1a and 1b ($K_i = 2.8 \pm 0.6$ and 33 ± 1 nM, respectively)^[3]. Thus, the present results additionally support our previous conclusion that the 5-HT_{1A} ligands 1-3 may be recognized at the receptor in such a manner that the aryl substituent at position 1 of the 3(2H)-isoquinolinone moiety and the basic nitrogen atom of the terminal amine function mimics remarkably well simple 1-arylpiperazines.

Experimental Part

Melting points: Boetius apparatus (uncorrected).– Elemental analyses: Within \pm 0.4% of calculated values for C,H, and N. Institute of Organic Chemistry, Warszawa.– ¹H NMR spectra (CDCl₃): Varian EM-360L (60 MHz) spectrometer, TMS int. standard.– Materials: **6a**, **7a** and other starting materials were commercial products (Aldrich); 1-(3-chlorophenyl)-1,4-dihydro-3(2H)-isoquinolinone was obtained according to the published procedure^[14].

I-(3-Chlorophenyl)-2-{3-[2-(1,2,3,4-tetrahydroisoquinolinyl)]propyl}-1,4-dihydro-3(2H)-isoquinolinone hydrochloride (3)

A mixture of 1-(3-chlorophenyl)-1,4-dihydro-3(2*H*)-isoquinolinone (0.26 g, 1 mmol), 2-(3-chloropropyl)-1,2,3,4-tetrahydroisoquinoline (0.21 g, 1.02 mmol), KF/Al₂O₃ catalyst (1.0 g), KI (0.02 g) and MeCN (15 ml) was refluxed for 4 h. The reaction mixture was filtered off and the solvent was evaporated. The oily residues was purified by CC (SiO₂, CHCl₃/MeOH - 9/1), then Al₂O₃/CHCl₃) to give 24% of **3**. Free base of **3** was transformed into HCl salt in acetone with an excess of Et₂O saturated with gaseous HCl. The resultant crystalline salt was recrystallized from CHCl₃/Et₂O (1/1). Mp 121-123 °C.- ¹H NMR (base): 1.8-2.2 (m, 2H, CH₂), 2.4-3.1 (m, 8H, 4 CH₂), 3.4 (s, 2H, isoquinoline *CH*₂N), 3.75 (s, 2H, *CH*₂O), 5.8 (s, 1H, CH), 7.0-7.4 (m, 12H, aromatic H).- Anal. C₂₇H₂₇ClN₂O · HCl).

General procedure for preparation of derivatives 4e, 4f, 6d, 8a, and 8b

A mixture of benzotriazole (0.95 g, 8 mmol) and cinnamaldehyde (0.53 g, 4 mmol) or crotonaldehyde (0.28 g, 4 mmol) in Et₂O (30 ml, freshly distilled from Na/benzophenone) was stirred at room temp. for 6 h and left overnight. The reaction mixture was cooled in an ice-water bath and a solution of an appropriate amine (4 mmol) was added in one portion upon stirring. Then the mixture was allowed to reach room temp. and the stirring was continued for 20 h. Afterwards the solvent was evaporated, the residue was dissolved in dioxane (40 ml), treated with NaBH₄ (0.076 g, 2 mmol), refluxed for 4 h and left overnight at room temp. The reaction mixture was poured into 10% NaOH (40 ml) and extracted with Et₂O (3 × 30 ml). The combined organic layers were washed with water and dried over anhydrous MgSO4. Then the solvent was evaporated, and the crude products were purified by CC (SiO₂, AcOEt/n-hexane – 1:2). The products were converted into HCl salts in acetone with an excess of Et₂O/HCl.

1-(o-Methoxyphenyl)-4-[(E)-cinnamyl]piperazine dihydrochloride (4e)

Yield 40%. Mp 183–185 °C (acetone/ethanol – 9:1).– ¹H NMR (base): 2.6–2.9 (m, 4H, 2 CH₂), 3.0–3.3 (m, 6H, 3 CH₂), 3.8 (s, 3H, OCH₃), 6.1–6.6 (m, 2H, CH=CH), 6.8–7.1 m, 4H, aromatic H), 7.2–7.5 (m, 5H, aromatic H).-Anal. ($C_{20}H_{24}N_2O \cdot 2$ HCl).

I-[3-(Benzotriazol-1-yl)-3-phenylpropyl]-4-(2-methoxyphenyl)piperazine(4f)

Yield 26%. Mp. 95–97 °C (*n*-hexane).– ¹H NMR: 2.3–3.3 (cluster, 12H, piperazine H and CH₂CH₂), 3.85 (s, 3H, OCH₃), 6.1 (t, J = 7 Hz, 1H, CH₂CH), 7.1 (s, 2H, aromatic H), 7.2–7.7 (m, 10H, aromatic H), 8.0–8.3 (m, 1H, benzotriazole 4-H).

N-[(E)-Cinnamyl]-1,2,3,4-tetrahydroisoquinoline hydrochloride (6d)

Yield 15%. Mp 220–221 °C (acetone/ethanol – 9:1).- ¹H NMR (base): 2.75–3.0 (m, 4H, CH₂CH₂), 3.4 (d, J = 6 Hz, 2H, CH_2 CH=CH), 3.7 (s, 2H, CH₂), 6.4–6.7 (m, 2H, CH=CH), 6.9–7.6 (m, 9H, aromatic H).- Anal. (C₁₈H₁₉N · HCl).

N-[3-(Benzotriazol-1-yl)-3-methylpropyl]morpholine hydrochloride (8a)

Yield 9%. Mp 180–182 ^oC (acetone), ref.^[15] 153–155 ^oC (picrate salt).– ¹H NMR (base): 1.75 (d, J = 7 Hz, 3H, CH₃), 2.1–2.6 (m, 8H, CHCH₂CH₂N and CH₂NCH₂), 3.65 (t, J = 5 Hz, 4H, CH₂OCH₂), 4.9–5.3 (m, 1H, CHCH₃), 7.3–7.65 (m, 3H, benzotriazole 4,5,6-H), 8.0–8.25 (m, 1H, benzotriazole 7-H).– Anal. (C₁₄H₂₀N₄O · HCl).

N-[3-(Benzotriazol-2-yl)-3-methylpropyl]morpholine hydrochloride (8b)

Yield 8%. Mp 193–195 °C (acetone).– ¹H NMR (base): 1.8 (d, J = 7 Hz, 3H, CH₃), 2.2–2.5 (m, 8H, CHCH₂CH₂N and CH₂NCH₂), 3.6–3.8 (m, 4H, CH₂OCH₂), 5.1–5.4 (m, 1H, CHCH₃), 7.4–7.6 (m, 2H, benzotriazole 5,6-H), 7.9–8.1 (m, 2H, benzotriazole 4,7-H).– Anal. (C₁₄H₂₀N₄O · HCl).

General procedure for preparation of derivatives 6b, 6c, 7b, and 7c

A mixture of **6a** or **7a** (3 mmol), the appropriate ω -phenylalkylbromide (3.1 mmol), anhydrous K₂CO₃ (0.5 g, 3.6 mmol), and *n*-butanol (20 ml) was refluxed for 10–12 h. Then the reaction mixture was cooled down, filtered off, and the solvent was evaporated. The residue was purified by CC (SiO₂, AcOEt/*n*-hexane – 1:1 for **6b** and **6c**, and CHCl₃/*n*-hexane – 1:1 for **7b** and **8c**). Free bases were converted into salts in acetone solutions using an excess of Et₂O, saturated with HCl or 40% aqueous HBr.

N-(2-Phenylethyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride (6b)

Yield 42%. Mp 228–231 °C (acetone, ref.^[16] 227–229 °C).– ¹H NMR (base): 2.5–3.1 (m, 8H, 4 CH₂), 3.65 (s, 2H, CH₂), 7.1 (s, 4H, aromatic H), 7.3 (m, 5H, aromatic H).– Anal. ($C_{17}H_{19}N \cdot HCl$).

N-(3-Phenylpropyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride (6c)

Yield 40%. Mp 203–205 °C (acetone, ref.^[16] 207–209 °C).– ¹H NMR (base): 1.7–2.2 (m, 2H, CH₂), 2.3–3.1 (m, 8H, 4 CH₂), 3.6 (s, 2H, CH₂), 7.0–7.5 (m, 9H, aromatic H).– Anal. (C₁₈H₂₁N · HCl).

N-(-Phenylethyl)-1,2,3,4-tetrahydroquinoline hydrobromide (7b)

Yield 38%. Mp 137–140 °C (acetone).– ¹H NMR (base): 1.8–2.2 (q, J = 6 Hz, 2H, *CH*₂Ph), 2.6–3.75 (m, 8H, 4 CH₂), 6.6–7.25 (m, 4H, aromatic H), 7.3 (s, 5H, aromatic H).– Anal. (C₁₇H₁₉N · HBr).

N-(3-Phenylpropyl)-1,2,3,4-tetrahydroquinoline hydrobromide (7c)

Yield 55%. Mp 161–164 $^{\circ}$ C (acetone).– ¹H NMR (base): 1.7–2.2 (m, 2H, CH₂), 2.4–2.9 (m, 4H, 2 CH₂), 3.0–3.6 (m, 6H, 3 CH₂), 6.4–7.2 (m, 4H, aromatic H), 7.25 (s, 5H, aromatic H).– Anal. (C₁₈H₂₁N · HBr).

Binding experiments

In vitro binding studies with 5-HT_{1A} receptors were carried out in the rat brain (hippocampus) using [3 H]-8-OH-DPAT (190 Ci/mmol, Amersham) as a radioligand^[17]. The K_i values were obtained in at least three independent, competition binding experiments, in which 10–14 drug concentrations run in triplicate were used.

pKa measurements

Ionization constants were determined by a potentiometric titration at 37 ± 0.1 °C in water or 50% ethanol. The pKa values were calculated from the experimental data by a standard method^[8] using an Enzfitter program (Biosoft, Oxford).

Molecular modelling

All the molecular modelling experiments were performed using a SYBYL v. 6.03 (Tripos Associates, Inc.) integrated package, installed on an ESV 10/33 workstation. The geometry of all the analyzed compounds was optimized using a Tripos force field procedure. Low-energy conformations were generated using a RANDOM SEARCH procedure (only chain bonds were allowed to rotate). The following setup was used to do calculations: minimization details – method: Powell, max iteration: 3000, max displacement: 0.01; energy – force field: Tripos; random search details - max cycles: 1000, energy cutoff: x + 5 kcal/mol, number of hits: 3, RMS threshold: 0.1, convergence threshold: 0.005.

References

- Part 22: J. L. Mokrosz, B. Duszynska, M. H. Paluchowska, S. Charakchieva-Minol, M. J. Mokrosz, Arch. Pharm. (Weinheim) 1995, 328, 623–625.
- [2] R. A. Glennon, R. B. Westkaemper, P. Bartyzel in Serotonin Receptor Subtypes: Basic and Clinical Aspects (Ed.: S. J. Peroutka), Wiley-Liss, New York, 1991, chapter 2.
- [3] J. L. Mokrosz, A. J. Bojarski, M. Mackowiak, Z. Bielecka, J. Boksa, *Pharmazie* 1994, 49, 328–333.
- [4] A. J. Bojarski, M. J. Mokrosz, M. H. Paluchowska, Pharmazie, in press.
- [5] S. Caccia, M. H. Fong, R. Urso, J. Pharm. Pharmacol. 1985, 37, 567–570.
- [6] A. R. Katritzky, S. Rachwal, G. J. Hitchings, *Tetrahedron* 1991, 47, 2683–2732.
- [7] J. L. Mokrosz, J. Boksa, A. J. Bojarski, S. Charakchieva-Minol, Med. Chem. Res. 1993, 3, 240–248.
- [8] A. Albert, E. P. Serjeant, *Ionization Constants of Acids and Bases*, Methuen, London, **1967**.
- [9] J. L. Mokrosz, M. Pietrasiewicz, B. Duszynska, M. T. Cegla, J. Med. Chem. 1992, 35, 2369–2374.

- [10] J. L. Mokrosz, M. J. Mokrosz, S. Charakchieva-Minol, M. H. Paluchowska, A. J. Bojarski, B. Duszynska, Arch. Pharm. (Weinheim) 1995, 328, 143-148.
- [11] J. L. Mokrosz, M. J. Mokrosz, A. J. Bojarski, S. Charakchieva-Minol, *Pharmazie* 1994, 49, 781–782.
- [12] M. F. Hibert, M. W. Gittos, D. N. Middlemiss, A. K. Mir, J. R. Fozard, J. Med. Chem. 1988, 31, 1087–1093.
- [13] M. F. Hibert, I. McDermott, D. N. Middlemiss, A. K. Mir, J. R. Fozard, *Eur. J. Med. Chem.* **1989**, 24, 31–37.
- [14] J. L. Mokrosz, M. T. Cegla, E. Szneler, Arch. Pharm. (Weinheim) 1992, 325, 241–245.
- [15] A. R. Katritzky, S. Rachwal, C. V. Hughes, Z. Wang, Polish J. Chem. 1992 66, 1633–1652.
- [16] Beilstein Handbuch der Organischen Chemie, E III/IV, 20, 2954.
- [17] A. J. Bojarski, M. T. Cegla, S. Charakchieva-Minol, M. J. Mokrosz, M. Mackowiak, S. Misztal, J. L. Mokrosz, *Pharmazie* 1993, 48, 289–294.

Received: April 21, 1995 [FP011]